Figure 2. Percentage of cells expressing CD11b for WT HL-60 and R38+ and R38- RA-resistant HL-60 cells.

D₃ increases the differentiation marker CD11b in RA-resistant HL-60 cell lines. (A) 48 h CD11b expression after sequential treatment with two inducing agents during the precommitment and lineage-commitment phases (RA/RA, RA/D₃, RA/-, D₃/D₃, D₃/RA, and D₃/-). (B) 72 h CD11b expression (continuation of treatment with second inducing agent). CD11b expression was assessed by flow cytometry (with APC-conjugated antibody) at 48 and 72 h after first treatment initialization. Gates to determine percent increase of expression with treatment were set to exclude 95% of the control population. For clarity, p-values are not indicated above bars due to the existence of multivariate comparison between cell lines, treatments, and time. However, p-values of interest are mentioned specifically in the main text.